Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables - Accured: 2021-2024

Historic Receivables - Accured for Janux Therapeutics (JANX) over the last 4 years, with Dec 2024 value amounting to $5.4 million.

  • Janux Therapeutics' Receivables - Accured rose 40.00% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 40.00%. This contributed to the annual value of $5.4 million for FY2024, which is 145.45% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Receivables - Accured is $5.4 million, which was up 145.45% from $2.2 million recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Receivables - Accured peaked at $5.4 million during FY2024, and registered a low of $200,000 during FY2021.
  • Over the past 3 years, Janux Therapeutics' median Receivables - Accured value was $2.2 million (recorded in 2023), while the average stood at $2.8 million.
  • Data for Janux Therapeutics' Receivables - Accured shows a peak YoY soared of 250.00% (in 2022) over the last 5 years.
  • Janux Therapeutics' Receivables - Accured (Yearly) stood at $200,000 in 2021, then surged by 250.00% to $700,000 in 2022, then surged by 214.29% to $2.2 million in 2023, then surged by 145.45% to $5.4 million in 2024.